Cargando…

A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab

INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukunaga, Hiroyuki, Sumii, Kenta, Kawamura, Shun, Okuno, Masato, Taguchi, Isao, Kawabata, Gaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626353/
https://www.ncbi.nlm.nih.gov/pubmed/36341187
http://dx.doi.org/10.1002/iju5.12532
_version_ 1784822712983617536
author Fukunaga, Hiroyuki
Sumii, Kenta
Kawamura, Shun
Okuno, Masato
Taguchi, Isao
Kawabata, Gaku
author_facet Fukunaga, Hiroyuki
Sumii, Kenta
Kawamura, Shun
Okuno, Masato
Taguchi, Isao
Kawabata, Gaku
author_sort Fukunaga, Hiroyuki
collection PubMed
description INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. CONCLUSION: A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event.
format Online
Article
Text
id pubmed-9626353
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96263532022-11-03 A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab Fukunaga, Hiroyuki Sumii, Kenta Kawamura, Shun Okuno, Masato Taguchi, Isao Kawabata, Gaku IJU Case Rep Case Reports INTRODUCTION: Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. CASE PRESENTATION: The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. CONCLUSION: A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event. John Wiley and Sons Inc. 2022-09-24 /pmc/articles/PMC9626353/ /pubmed/36341187 http://dx.doi.org/10.1002/iju5.12532 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Fukunaga, Hiroyuki
Sumii, Kenta
Kawamura, Shun
Okuno, Masato
Taguchi, Isao
Kawabata, Gaku
A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title_full A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title_fullStr A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title_full_unstemmed A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title_short A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
title_sort case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626353/
https://www.ncbi.nlm.nih.gov/pubmed/36341187
http://dx.doi.org/10.1002/iju5.12532
work_keys_str_mv AT fukunagahiroyuki acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT sumiikenta acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT kawamurashun acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT okunomasato acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT taguchiisao acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT kawabatagaku acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT fukunagahiroyuki caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT sumiikenta caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT kawamurashun caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT okunomasato caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT taguchiisao caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab
AT kawabatagaku caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab